



- [About the FMI](#)
- [Research](#)
- [Technical resources](#)
- **[Licensing opportunities](#)**
- [News](#)
- [Seminars/Conferences](#)
- [Graduate studies](#)
- [Teaching](#)
- [Open positions](#)
- [Links](#)

## LICENSING OPPORTUNITIES



FMI

 go back

 back/  
next




---

<b>Title (priority date):</b>	<b>Uses and methods relating to ndr kinaseexpression and/or activity (29.11.2006)</b>
<b>Reference:</b>	045
<b>Inventors:</b>	Cornils, Dirnhofer & Hemmings
<b>Description:</b>	The inventors observed that lymphoma development due to abherent NDR1 and/or NDR2 expression is late onset. This suggest that early detection of abherent NDR1 and/or NDR2 expression may allow for treatmetn before disease occurs.
<b>Applications:</b>	Cancer therapy, screening for anti-cancer agents
<b>Status:</b>	PCT pending
<b>Opportunity:</b>	Exclusive or non-exclusive licenses
<b>Publications:</b>	
<b>Contact:</b>	Dr. Nicolas Favre, tel: +41 61 6978382, e-mail: nicolas.favre@fmi.ch
<b>PCT File:</b>	WO2008/065391

---